Aerie Pharmaceuticals reported $-32039000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Aerie Pharmaceuticals AERI:US $ -32.04M 85.4M
Alimera Sciences ALIM:US $ -3.46M 1.36M
Amarin AMRN:US $ -27.53M 44.04M
Cara Therapeutics CARA:US $ -27848000 5.61M
Coherus Biosciences CHRS:US $ -80.12M 41.48M
Endo International Ordinary Shares ENDP:US $ 226.56M 52.35M
Horizon Pharma HZNP:US $ 291.56M 100.61M
Insmed INSM:US $ -98173000 1.78M
JAZZ PHA JAZZ:US $ 267.26M 90.66M
Merk MRK:US $ 6179M 492M
Mirati Therapeutics MRTX:US $ -183.59M 12.92M
Novartis NOVN:VX SF 4552M 346M
Ophthotech OPHT:US $ -34.65M 1.57M
Pacira Pharmaceuticals PCRX:US $ 41.76M 17.12M
Regeneron Pharmaceuticals REGN:US $ 1360.9M 1353.3M
Revance Therapeutics RVNC:US $ -56.84M 0.66M
Supernus Pharmaceuticals SUPN:US $ 23.33M 17.79M
Teva Pharmaceutical Industries TEVA:US $ 1112M 176M
Valeant Pharmaceuticals VRX:CN $ 660M 156M
Zoetis ZTS:US $ 908M 194M